{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04972942",
            "orgStudyIdInfo": {
                "id": "NYMC-598"
            },
            "organization": {
                "fullName": "New York Medical College",
                "class": "OTHER"
            },
            "briefTitle": "Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma",
            "officialTitle": "Phase I Trial of Targeted Immunotherapy With Daratumumab Following Myeloablative TBI-Based Conditioning and AlloHCT in Children, Adolescents and Young Adults With High Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (ALLO-T-DART)",
            "acronym": "ALLO-T-DART",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "targeted-immunotherapy-after-myeloablative-tbi-based-conditioning-allohct-in-caya-with-high-risk-t-cell-all-lymphoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-05-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-07-13",
            "studyFirstSubmitQcDate": "2021-07-13",
            "studyFirstPostDateStruct": {
                "date": "2021-07-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-06-29",
            "lastUpdatePostDateStruct": {
                "date": "2023-07-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "New York Medical College",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy).\n\nPre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoing allogeneic HCT and post-HCT DARA treatment. The study will also evaluate T-cell repertoire and immune reconstitution prior to and following DARA post-HCT treatment and correlate with patient outcomes.",
            "detailedDescription": "Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.\n\nDaratumumab (DARA) treatment post-HCT:\n\nPhase 1: 3 dose levels to determine safety (15 patients)\n\nDose expansion cohort (DEC): Further evaluation of PK and PD (correlative studies/exploratory endpoints) to guide future selection of RP2D (15 patients)\n\nTreatment Schedule:\n\n1. Induction: DARA IV weekly x 8 doses (Weeks 1-8)\n2. Consolidation: DARA IV every 2 weeks x 8 doses (Weeks 9-24)\n3. Maintenance: DARA IV every 4 weeks (Stop at Day +270)"
        },
        "conditionsModule": {
            "conditions": [
                "T-cell Acute Lymphoblastic Leukemia",
                "T-Cell Acute Lymphoblastic Lymphoma"
            ],
            "keywords": [
                "immunotherapy",
                "children",
                "adolescents",
                "young adults"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Phase 1: 3 dose levels to determine safety. Followed by dose expansion cohort.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Interventional",
                    "type": "OTHER",
                    "description": "Phase 1: 3 dose levels to determine safety (15 patients)\n\nDose expansion:\n\nDaratumumab (DARA) treatment post-HCT\n\n1. Induction: DARA IV weekly x 8 doses (Weeks 1-8)\n2. Consolidation: DARA IV every 2 weeks x 8 doses (Weeks 9-24)\n3. Maintenance: DARA IV every 4 weeks (Stop at Day +270)",
                    "interventionNames": [
                        "Drug: Daratumumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Daratumumab",
                    "description": "Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.\n\nDaratumumab (DARA) treatment post-HCT Phase 1: 3 dose levels to determine safety (15 patients)\n\nDose expansion:\n\n1. Induction: DARA IV weekly x 8 doses (Weeks 1-8)\n2. Consolidation: DARA every 2 weeks x 8 doses (Weeks 9-24)\n3. Maintenance: DARA every 4 weeks (Stop at Day +270)",
                    "armGroupLabels": [
                        "Interventional"
                    ],
                    "otherNames": [
                        "Darzalex\u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Patients with dose limiting toxicity (per CTCAE v.5)",
                    "description": "occurrence of any Grade \u2265 3 non hematologic toxicity (per CTCAE v.5) which is probably, or definitely related to daratumumab",
                    "timeFrame": "60 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Relapse free survival",
                    "description": "To measure relapse free survival in patients post HCT and daratumumab",
                    "timeFrame": "1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* 0-39yrs\n* T-cell ALL in second or subsequent remission (\u2264 5% blasts) or relapsed T-cell LLy with complete response after re-induction therapy\n* Planned allogeneic stem cell transplantation with donor identified\n* Performance status \u2265 60%\n* Fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\n* Meet organ function requirements\n* Signed IRB approved informed consent\n\nExclusion Criteria:\n\n* May not have had a prior autologous or allogenic stem cell transplant\n* May not have uncontrolled, systemic infection at the time of enrollment\n* Known allergies, hypersensitivity, or intolerance to mannitol, sorbitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients\n* Must not be pregnant or actively breast feeding\n* Seropositive for HIV, hepatitis B or hepatitis C\n* COPD\n* Asthma\n* Clinically significant cardiac disease",
            "healthyVolunteers": false,
            "sex": "ALL",
            "maximumAge": "39 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lauren Harrison, RN, MSN",
                    "role": "CONTACT",
                    "phone": "6172857844",
                    "email": "lauren_harrison@nymc.edu"
                },
                {
                    "name": "Erin Morris, RN",
                    "role": "CONTACT",
                    "phone": "7149645359",
                    "email": "erin_morris@nymc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Mitchell Cairo, MD",
                    "affiliation": "New York Medical College",
                    "role": "STUDY_CHAIR"
                },
                {
                    "name": "Troy Quigg, DO",
                    "affiliation": "Helen DeVos Children's Hospital",
                    "role": "STUDY_CHAIR"
                },
                {
                    "name": "Allyson Flower, MD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "New York Medical College",
                    "status": "RECRUITING",
                    "city": "Valhalla",
                    "state": "New York",
                    "zip": "10595",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mitchell Cairo, MD",
                            "role": "CONTACT",
                            "phone": "914-594-3650",
                            "email": "mitchell_cairo@nymc.edu"
                        },
                        {
                            "name": "Lauren Harrison, MSN",
                            "role": "CONTACT",
                            "phone": "617-285-7844",
                            "email": "lauren_harrison@nymc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.07482,
                        "lon": -73.77513
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000054198",
                    "term": "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
                },
                {
                    "id": "D000007945",
                    "term": "Leukemia, Lymphoid"
                },
                {
                    "id": "D000054218",
                    "term": "Precursor T-Cell Lymphoblastic Leukemia-Lymphoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27585",
                    "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10951",
                    "name": "Leukemia, Lymphoid",
                    "asFound": "Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27587",
                    "name": "Precursor T-Cell Lymphoblastic Leukemia-Lymphoma",
                    "asFound": "T-cell Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T175",
                    "name": "Acute Lymphoblastic Leukemia",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3533",
                    "name": "Lymphoblastic Lymphoma",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000556306",
                    "term": "Daratumumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M272211",
                    "name": "Daratumumab",
                    "asFound": "Kidney Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}